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An endothelin-1 mediated autocrine growth loop involved in human
renal tubular regeneration. Renal tubules have the capacity to regenerate
following injury. We have investigated the possibility that tubular-derived
endothelins, acting as autocrine growth factors, may be involved in this
response in human kidney. ET-1 immunoreactivity was demonstrated by
immunohistochemical staining in proximal tubules, distal cortical tubules
and medullary collecting ducts of human kidney. In cultured human renal
proximal tubular cells, RNAase protection assays demonstrated the
expression of ET-1 and ET-2 mRNA's, and radioimmunoassay, following
separation of conditioned medium by reverse phase HPLC, showed
immunoreactive material which co-eluted with ET-1 and ET-2. Competi-
tion binding studies revealed the presence of at least two types of
endothelin receptor: one with high and one with low affinity for ET-3
relative to ET-1. Analysis of cellular RNA by RT-PCR demonstrated
expression of mRNA's for both ETA and ETa receptor subtypes. Com-
bined blockade of ETA ETB receptors (by PD- 145065) but not that of
ETA receptors alone (by BQ-123) blocked the mitogenic effect of exoge-
nous or endogenous ET-1 and also profoundly suppressed endogenous
FT-i synthesis. By contrast, incubation with the ET receptor agonist,
BQ-3020, stimulated endogenous ET-i synthesis. Exposure of the cells to
hypoxia (1% 02 for 16 to 24 hr) resulted in specific up-regulation of ET-1
but not ET-2 gene expression. These findings reveal the existence of a
hypoxia-inducible, autocrine growth system in human proximal tubular
cells, which is mediated by ET-1 through the ETB receptor, and which
could function in vivo as an autoregenerative system for restoring tubular
integrity after injury. The widespread distribution of ET-1 peptide in
different tubular segments suggests that ET-1 mediated tubular regener-
ation may also occur in other nephron segments.
Acute renal failure most commonly arises in the context of
hemodynamic disturbance and is associated with ischemic necro-
sis of renal tubules [11. Since full renal recovery does occur in the
vast majority of cases, the capacity of tubular cells, especially
proximal tubular cells, which arguably bear the brunt of the
ischemic process [2], to repair and regenerate themselves must be
considerable. Although the process of tubular regeneration re-
mains poorly understood, it seems likely that a multiplicity of
growth systems, such as endocrine, paracrine and autocrine, are
involved in renal tubular regeneration [1]. Several well-character-
ized polypeptide growth factors such as epidermal growth factor
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(EGF), hepatocyte growth factor (HGF) and insulin-like growth
factor-I (IGF-I) are normally synthesized in the kidney [3]. There
is indirect evidence implicating these growth factors in the process
of renal regeneration [4—9]. It is therefore tempting to speculate
that renal regeneration following ischemia results from an in-
crease in endogenous renal synthesis of polypeptide growth
factors. Direct evidence of this has, however, been conflicting,
since renal growth factor gene expression in the ischemic kidney
may increase such as HGF [10] or decrease such as EGF [9] and
IGF-I [8]. It is also unlikely that such factors operate in all tubular
segments, since growth factor synthesis in the normal and isch-
ernie kidney remain restricted to specific tubular segments [3, 11].
The endothelins are a family of novel peptides with particularly
potent vasoactive [12] and mitogenic actions [13]. Endothelin,
since renamed FT-i, was initially isolated from conditioned media
of porcine aortic endothelial cells [14]. Subsequent screening of a
human eDNA library by low stringency hybridization revealed the
existence of three separate human endothelin genes encoding
three related peptides: FT-i, ET-2 and ET-3 [12]. Examination of
other species has shown striking conservation of the three endo-
thelin genes throughout evolution, suggesting that they encode
peptides with important biological functions. Multiple non-endo-
thelial cell types in a variety of organs including mesangial cells
[15] and renal tubular epithelial cells [16] appear to bind and/or
synthesize endothelins, making it seem likely that the endothelins
have a variety of non-cardiovascular functions, including the
regulation of sodium transport [17, 18], cell growth [13, 19] and
differentiation during embryonic development [20].
Several observations suggested to us that tubular-derived ET-1
(probably the main contributor to total renal ET-1 synthesis)
might play a role in the regenerative process in human renal
proximal tubules following ischemia, possibly as an autocrine
growth factor which could be up-regulated by cellular hypoxia.
First, the level of ET-i rnRNA in the rat kidney is markedly
increased during the period of recovery which follows removal of
a clamp on the renal artery, and the increase persists for up to
seven days [21]; second, hypoxia is known to up-regulate ET-1
synthesis in vitro in human umbilical vein endothelial cells
(HUVEC) [22]; third, ET-1 is a potent mitogen in cell types other
than tubular cells [23]. Because multiple renal cells are known to
synthesize FT-i constitutively, we have investigated this hypoth-
esis using an in vitro cell culture model of human renal proximal
tubular cells.
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Methods
Immunohistochemical localization of endothelin in human kidney
Immunohistochemical staining for ET-1 in human renal biopsy
tissue was performed on renal tissue obtained from ten patients
with normal renal function (median plasma creatinine 90 mol/
liter) biopsied because of microscopic hematuria. Histologically,
all the biopsies were normal in appearance on light microscopy. A
diagnosis of thin membrane disease was made in six patients
based on electron microscopy; no definite cause for the hematuria
was found in the remaining four patients. The median age was 52
years and male:female ratio was 4:6. Tissue was fixed in 10%
neutral buffered formalin and embedded in paraffin. Three to 5
jm sections were transferred onto silanized glass slides, dried at
room temperature and then for 30 minutes at 56°C. Sections were
deparaffinized through xylene, graded concentrations of ethanol
and distilled water. Endogenous peroxidase was blocked with
0.5% hydrogen peroxide dissolved in methanol for up to 15
minutes. A high affinity (K 4.4 X 1010 liter/M) monoclonal
antibody, with equal cross reactivity to ET-1, and Big ET-1, which
we have generated and described previously [24], was used as the
primary antibody. Tissue sections were incubated for 30 to 45
minutes with various dilutions of the primary antibody. A biotin-
ylated rabbit anti-mouse antibody (1/20 dilution) was used as the
secondary antibody, and normal human serum was added simul-
taneously to reduce non-specific binding. Binding of the second-
ary antibody was detected with a streptavidin-ABC complex
linked to horseradish peroxidase, developed with 3'3-diaminoben-
zidine (DAB) solution, and the sections counterstained with
hematoxylin. Control sections were stained, omitting either pri-
mary or secondary antibodies or using equivalent concentrations
of mouse ascites as the primary antibody. The strength of ET-1
immunoreactivity in three tubular segments, that is, proximal
tubules (N = 8), cortical distal tubules (N = 8) and inner
medullaiy collecting ducts (N = 4) was compared by densitomet-
nc analysis using the COLORMORPH program (Perspective
Instruments Ltd., Essex, UK). Where sufficient tissue was avail-
able for analysis, at least 5 high power fields per section, chosen at
random, were quantified to obtain a mean value for each tubular
segment.
Culture and characterization of human proximal tubular cells
To investigate the regulation of endothelin synthesis in human
tubular cells, human renal cortical epithelial cells, derived from
the unaffected pole of renal cortex obtained from nephrectomy
specimens removed for malignancy or from cadaveric kidneys
(considered unsuitable for transplantation for technical reasons),
were cultured on collagen-coated flasks as previously described
[24—26]. Cells were grown in DMEM/F12 supplemented with
triiodothyronine (4 pg/ml), hydrocortisone (36 ng/ml), insulin (5
j.g/ml), transferrin (5 j.Lg/ml), selenium (5 ng/ml) and epidermal
growth factor (10 nglml) [27]. Cultured cells demonstrated char-
acteristics of a highly enriched population of proximal tubular
cells as previously described [24—26]. Contamination by endothe-
hal cells was excluded by uniform negative staining for Von
Willebrand factor. At early passages, dome formation was ob-
served, indicating vectorial fluid transport. The cells formed
tubular structures with lumens in a three-dimensional Type I
collagen gel even at late passage, indicating that they retained
polarity. Cyclic AMP production in these cells was up-regulated
by parathyroid hormone (PTH, 1 M) but not by arginine-
vasopressin (AVP, 1 jIM) in the presence of 3-isobutyl-methyl-
xanthine (IBMX) (data not shown). Only cells up to passage 5
were used.
Separation of endothelin peptides in conditioned medium by
reverse-phase high performance liquid chromatography
(RP-HPLC)
Conditioned medium from confluent monolayers of human
PTC (passages 2 to 4) grown in serum-free defined medium was
pooled and frozen at —70°C. After thawing, 500 ml of pooled
supematant was acidified with acetic acid (100%) and concen-
trated through a Sep-pak C18 column as described by Kosaka et
al [28]. Material retained on the column was eluted in 4 ml of an
ethanol (86%), acetic acid (4%) and water (10%) mixture. The
eluate was dried under nitrogen, redissolved in 1 ml of ethanol
and dried again. Immediately prior to chromatography on a C18
column (Aquapore 0D300, 4.6 X 100 mm; Applied Biosystems
Inc., San Jose, CA, USA), the preparation was redissolved in 100
.d of acetonitrile (100%) containing 0.1% trifluoroacetic acid.
Using a flow rate of 0.5 ml/min, the gradient of acetonitrile was
increased linearly from 0 to 20% over five minutes and 20 to 40%
over 30 minutes. Preliminary work had shown that this gradient
provided clear separation of standards (1 nmol) of ET-1, ET-2,
ET-3 and ET-1 sulphoxide. ET-1 suiphoxide was generated by
oxidation of ET-1 with 0.5% hydrogen peroxide in 1 M formic acid
at 30°C for six hours [29}. 0.25 ml fractions were collected every
0.5 minute, dried in a vacuum centrifuge and kept at —70°C until
assayed. The recovery of ET-1 standard using this procedure was
90%.
Endothelin immunoassays
Cell supernatants were assayed for immunoreactive endothelin
(IR-ET) by an immunoradiometric assay (IRMA) specific for
ET-1 developed by us and reported previously [22, 24]. The assay
showed a 15% cross reaction with ET-2 and ET-3 throughout the
dose response curve, no cross reaction with Big ET-1 up to a level
of 500 ngfliter of sample and no cross reaction with human atrial
natriuretic peptide (<0.0001%). In addition, there was no cross-
reactivity with the ET analogues, BQ-123 (10—6 M), BQ-3020
(10 M) and PD-145065 (10 M) at the concentrations used. The
sensitivity of the assay (3 X SD of zero dose estimate) was 0.15
pg/tube, corresponding to 1.5 pg/ml in cell supernatants. Inter-
and intra-assay variations were 10% and 4.7%, respectively.
Fractionated samples from HPLC were also assayed using a
commercially available radioimmunoassay (RIA) (Nichols Insti-
tute Diagnostics, Wijchen, The Netherlands). The antibody used
in this assay cross-reacts with ET-1 (100%), ET-2 (52%), ET-3
(96%) and Big ET-1 (7%). The sensitivity of the assay is 2 pg/ml.
RNAase protection assays for human ET-1, ET-2 and ET-3
mRNAs
RNA extraction from human PTC was performed using a
one-step procedure (RNAzolB, Biogenesis Ltd, Bournemouth,
UK) [30] according to the manufacturer's instructions. Ribo-
probes specific for human ET-1, ET-2 and ET-3 mRNAs were
generated as previously described [31]. In brief, two-stage poly-
merase chain reactions (PCR) using partially nested primers
designed from known gene sequences were employed to amplify
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short genomic fragments of ET-1, ET-2 and ET-3; in each case
including part of the coding sequence from exon 2 (which encodes
the amino acids present in the mature peptides) together with
adjacent 5' intron. The fragments were cloned into appropriate
riboprobe vectors, linearized and used to produce specific labeled
antisense RNA transcripts by in vitro transcription with SP6
polymerase in the presence of [a-32P]GTP (Amersham Interna-
tional, Amersham, UK). For analysis of mRNA, precipitated total
RNA was dissolved in an aliquot of hybridization buffer (80%
formamide, 40 mrvt PIPES, 400 m sodium chloride, 1 mrvi EDTA
pH 8) and the RNA concentration determined by absorbance
measurements at 260 nm using a DU-62 spectrophotometer
(Beckman Instruments mc). The concentrations were adjusted to
yield 50 tl samples containing 30 tg of RNA, to each of which
was added 0.2 g of total RNA extracted from rat liver. This RNA
contained a high level of rat actin mRNA, cohybridization to a rat
actin riboprobe [32], providing an internal control to check that
RNA degradation, sample processing and gel loading were com-
parable between specimens. Hybridization was performed over-
night at 60°C with 5 X iO cpm of the appropriate ET probe and
5 x i05 cpm of rat actin probe. RNAase digestion was then
carried out at 37°C for 30 minutes, and terminated by the addition
of 60 d of proteinase K (1 mgfml) with 3% SDS and further
incubation at 37°C for 30 minutes. Phenol-chloroform and chlo-
roform extractions were performed and the RNA fragments
precipitated with 2.5 volumes of absolute alcohol. The precipi-
tated RNA was dissolved in 5 d of 80% formamide loading
buffer, and the reaction mix electrophoresed on a denaturing 8%
polyacrylamide gel. The gel was then dried and subjected to
autoradiography at —70°C, following which the protected ET and
rat actin mRNA bands were excised and radioactivity counted
using a liquid scintillation counter (model 1205 Beta Plate5,
Pharmacia-Wallac OY, Turkey, Finland). On a single gel, the
counts obtained from the actin bands never varied over a range of
more than 15%, indicating that there was no great variation in
RNA degradation, processing and gel loading between individual
samples. Statistical comparison of ET expression between exper-
imental and control groups was made by comparing counts,
normalized for actin recovery, using an unpaired t-test with a
two-sided P value of less than 0.05 being taken as indicating
significance.
Effect of hypoxia on ET-1, ET-2 and ET-3 gene expression
Human PTC were grown on 100 mm collagen-coated plates
were incubated at 37°C for between 16 to 24 hours under hypoxic
conditions by preinfusion of a preanalyzed gas mixture (1% 02,
5% C02, 94% N2) into an air-tight modular incubator (ICN
Biomedicals Ltd., Thame, UK). Medium P°2 achieved after this
period was measured at between 30 to 40 mm Hg using an
automated gas analyzer. As normoxic controls, cells were incu-
bated in the same incubator (20% 02, 5% C02) and the medium
P°2 was 140 to 150 mm Hg. In three experiments, cells were also
incubated in parallel with cobaltous chloride (50 ,LLM), a com-
pound which mimics the effect of hypoxia in up-regulating the
erythropoietin gene [33]. Total cellular RNA was harvested and
analyzed by RNAase protection assays for all three endothelin
mRNAs as described above. Cell supernatants were saved for
ET-1 assay by IRMA.
Reverse transcriptase polymerase chain reaction (PCR) detection
of ETA and ETB receptor mRNA
First strand cDNA was synthesised from 2.5 jg of total cellular
RNA using oligo(DT) primers and avian myoblastosis reverse
transcriptase. Nested PCR for ETA and ETB receptor mRNA was
performed using conditions described in detail in a previous paper
[34]. These PCR products had previously been cloned and se-
quenced on both strands and confirmed as human ETA and ETB
fragments by comparison with previously published sequences [35,
36]. Internal primer pairs yielded products of 299 base pairs for
ETA and 428 base pairs for ETC.
Cellular binding of '251-ET-1
Human PTC were plated in 24-well plates at a density of 1 X
io cells per well and left overnight. They were then preincubated
with binding medium (DMEM/F12 plus 0.1% bovine serum
albumin) at 37°C for 30 minutes, before the addition of 1251-ET-1
(Specific activity 2,000 Ci/mmol, Amersham International) in a
volume of 200 il at different concentrations and for different time
periods. Preliminary studies showed that binding of '251-ET-1 to
the cells at 4°C had not reached equilibrium by 24 hours;
therefore, all subsequent studies were performed at 37°C. Be-
cause of this, Bm values quoted may overestimate the total
binding capacity of ET-1 since they reflect both binding and
uptake of 125I-ET-1.
For saturation binding experiments, cells were incubated with
increasing concentrations of 1251-ET-1 for six hours. For compe-
tition binding experiments, increasing concentrations of unlabeled
ET-1, ET-3 or BQ-123, were also added to binding medium
containing 125I-ET-1 (100 pM). At the end of each experiment, cell
monolayers were washed extensively with ice-cold binding me-
dium and solubilized with 0.5 N NaOH. Bound and internalised
1251-ET-1 was estimated by gamma counting and total cell protein
per well measured by the Bradford method. Binding data were
analyzed by data transformation using a modified version of the
LIGAND/EBDA program (Elsevier).
DNA synthesis measured by [3H]-thymidine incorporation
Cells were plated in 24-well plates at a density of 1 x iO cells
per well and made quiescent by a 48 hour incubation with basal
medium (DMEMIF12) containing 5 jtml transferrin. In initial
studies, quiescent cells were then incubated for a further 24 hours
with different concentrations of ET-1, ET-2 or ET-3. In subse-
quent experiments, we found the mitogenic effect of exogenous
ET-1 to be variable; in some experiments, exogenous ET-1 (10_li
M to iO M) had no additional mitogenic effect, suggesting that
endogenous ET-1 release might be masking this effect. To block
the synthesis and action of endogenous ET-1, we preincubated
quiescent cells with phosphoramidon (10 which blocks the
ET-1 converting enzyme) and the specific endothelin receptor
antagonists, BQ-123 (10—6 which blocks ETA) and PD-145065
(10 which blocks ETA and ETB), respectively. The cells were
then pulsed with 1 tCi of [3H]-thymidine per well for 18 to 24
hours. After washing, cells were precipitated with 10% trichloro-
acetic acid (TCA) and solubilized with 0.5 N NaOH. An aliquot
was counted in a liquid scintillation counter and another assayed
for total cell protein per well.
To allow for the variability between different experiments
performed using cells from different sources, the results are
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expressed as percentage increases over control to enable compar-
ison between different experiments to be made.
Effect of ET analogues and phosphoramidon on endogenous ET-1
synthesis
ET-1 synthesis by tubular cells over 24 hours was measured to
study the effect of co-incubation with BQ-123, PD-145065, phos-
phoramidon, and the ETB receptor agonist, BQ-3020.
Materials
Endothelin standards (ET1, ET2, ET3) and BQ-123 were
obtained from the Peptide Institute (Osaka, Japan). PD-145065
was a gift of Dr. Annette Doherty (Parke-Davis, Ann Arbor, MI,
USA). BQ-3020 was purchased from Scientific Marketing Asso-
ciates (Barnet, Herts, UK). Enzymes were obtained from HT
Biotechnology (Cambridge, UK) and deoxynucleoside triphos-
phates from Pharmacia Ltd (Milton Keynes, UK). Except where
previously mentioned, all chemicals were obtained from Sigma
(Poole, Dorset, UK).
Statistical analyses
All results are expressed as means SEM unless otherwise
stated. Unpaired Student's t-test was used for statistical compar-
isons and considered significant if the P value was less than 0.05.
Results
Localization of ET-1 peptide in human tubular cells in vivo
Immunoreactive ET-1 was demonstrated in the glomeruli,
proximal tubules and all tubular segments as well as in the papilla
of human kidney (Fig. 1). In the cortex, both proximal tubules and
distal tubules stained positively for ET-1, although distal tubules
were more strongly positive (Fig. 1A); on some sections at higher
magnification (X 1000), ET-1 staining in proximal tubular cells
appeared to be localized to basal cell inclusions (Fig. 1C). Positive
staining was also seen in large vessel endothelium (Fig. 1H) but
not in the vasa recta (Fig. 1E). In the medulla, collecting ducts
(Fig. 1 D, E) and pelvic epithelium (Fig. 1G) exhibited positive
ET-1 immunoreactivity. The specificity of the staining was indi-
cated by the negative controls (Fig. 1 B, F). As assessed by
semiquantitative densitometric analysis in 8 specimens (with '0'
representing maximal density and '250' representing minimum
density), ET-1 staining in three tubular segments (mean su) was
highest in the cortical distal tubules (173 5), intermediate in
inner medullary collecting ducts (193 4) and lowest in proximal
tubular segments (208 2).
Human PTC synthesize ET-1 and ET-2 peptides
Since existing immunoassays cannot distinguish between ET-1
and ET-2, RP-HPLC was used to separate the different endothe-
lin isoforms present in conditioned medium from human PTC
prior to immunoassay. Three major immunoreactive peaks, cor-
responding to ET-1 sulphoxide (retention time 27.5 mi, ET-1
(retention time 29.5 mm) and ET-2 (retention time 30.5 mm),
were found in three separate experiments, as assayed by IRMA
(Fig. 2). The results by RIA were qualitatively identical, although
the peak for ET-2 was higher in line with the greater cross
reactivity of the antibody to ET-2 (data not shown). In one
experiment, a peak corresponding to ET-3 (retention time 25.5
mm) was found (data not shown), but this was not pursued further
since ET-3 mRNA was not detected (see below).
Human PTC express ET-1 and ET-2 mRNA, but hypoxia
up-regulates ET-1 gene expression only
Both ET-1 and ET-2 mRNA were detected in human PTC in
culture (Fig. 3). Exposure of tubular cells to hypoxia (16 to 24 hr)
resulted in increased expression of the ET-1 gene but not of the
ET-2 gene (1.1 0.1 of normoxic controls, N = 3; Fig. 3).
Expression of the ET-3 gene was not detected under normoxic or
hypoxic conditions in several experiments (data not shown). ET-1
steady-state mRNA levels in hypoxic cells were consistently
elevated by 2.6 0.1-fold (mean SEM, N = 7) after 16 to 24
hours of hypoxia (Fig. 4). ET-1 peptide was correspondingly
increased by roughly twofold in supernatants of hypoxic cells (181
17% of normoxic controls, N 6). In three experiments,
incubation with cobaltous chloride for 24 hours did not reproduce
the effect of hypoxia on ET-1 gene expression (Fig. 4) or peptide
synthesis (118 11% of normoxic controls, N = 3).
ETA and ET receptor genes are expressed in human PTC
Six separate samples of total RNA extracted from these cells
were examined for ETA and ETB receptor gene expression. Two
bands of 299 base pairs and 428 base pairs, corresponding to the
predicted amplified sequences for ETA and ETB, were found in all
six samples (Fig. 5).
Human PTC bind '251-ET-1 by two high-affinity receptors
The binding of 1251-ET-1 to tubular cells at 37°C was time-
dependent, reaching equilibrium by six hours and remaining
constant for a further six hours (data not shown). Scatchard
analysis of saturation binding of '251-ET-1 by PTC revealed a Kd
of 41 16 M (N = 3) and a single population of high aiffinity
receptors (Fig. 6A). Unlabeled ET-1 and ET-3 competed with the
binding of 1251-ET-1 with an IC50 of 0.33 0.04 nM (N = 4) and
320 37 nrvi (N = 5), respectively (Fig. 6B). Transformation of
competition binding data between unlabeled ET-1 and labeled
ET-1 by LIGAND revealed a K of 0.11 0.03 nM (N = 4) and a
one-site fit. In contrast, data transformation of competition
binding between unlabeled ET-3 and labeled ET-1 (Fig. 6B)
receptors with low and high affinity for ET-3 relative to ET-1,
corresponding to the described features of ETA and ETB recep-
tors: calculated values for I( (N = 5) for ET were 0.18 0.07 nM
and for ETA, 180 20 flM. Bm values for ETA and ETB were 8.3
1.3 fmol/jtg cell protein and 1.7 0.3 fmol/g cell protein,
respectively; the ratio of ETA/ETa was 5.5 1.4 (N = 5). These
Kd and I( values closely approximate those described for 125I
ET-1 and 1251-ET-3 binding to cultured rat [37J and porcine 38]
tubular cells. The ETA-specific receptor antagonist BQ-123 com-
peted with '251-ET-1 for binding with a K1 of 9 1 n (N =6) and
had an IC50 of 22 5 nM (N = 6), values similar to those
described for ETA receptors expressed by rat vascular smooth
muscle cells 39]. Bm,, for ETA receptors estimated in this way
was 7.5 1.6 fmol/tg cell protein.
ET-1 is an autocrine growth factor in human PTC
In initial studies, we found exogenous ET-1, ET-2 and ET-3 to
be roughly equipotent in stimulating DNA synthesis in quiescent
tubular cells: the maximum increase seen was twofold and the
'V I
* d "s
!i _.z.id
394 Ong et a!: ET-1 mediated tubular regeneration
0N H N H
4 ET-2
ET-1
Actui
400
- 300
.4—
I-
w
ci)>t 200
cci
ci)0C
E
E 100 -
0
0
Fraction number
Ong et al: ET-1 mediated tubular regeneration 395
40
Fig. 2. Immunoreactive endothelin in conditioned medium of human PTC
as assayed by IRIVIA following separation by reverse-phase HPLC as de-
scribed in the text. Three immunoreactive peaks corresponding to ET-1
suiphoxide (retention time 27.5 mm), ET-1 (retention time 29.5 mm) and
ET-2 (retention time 30.5 mm) were detected in three separate
experiments.
concentration inducing half-maximal response was approximately
1012 M for all three endothelins (Fig. 7A). In addition, the
mitogenic effect of exogenous ET-1 could be blocked by PD-
145065 (10 M) but not by BQ-123 (106 data not shown).
To block the effect of endogenous ET-1, cells were incubated
with phosphoramidon or PD-145065. Phosphoramidon (10 M)
or PD-145065 (10 M) both resulted in a 25% decrease in
[3H]-thymidmne incorporation (Fig. 7B). Co-incubation with both
compounds did not decrease basal DNA synthesis further (Fig.
7B). These effects were not related to cell toxicity since there was
no significant difference in total cell protein between wells and no
evidence of significant cell detachment after incubation (data not
Fig. 3. Hypoxia up-regulates ET-1 but not ET-2 gene expression in human
PTC. Human PTC were exposed to normoxic (20% 02) or hypoxic
conditions (1% 02) for 16 hours. Total RNAwas extracted and assayed by
RNAase protection assays for human ET-1 and ET-2 mRNA as described
in the text. ET-3 mRNA could not be detected in normoxic or hypoxic cells
(data not shown). These results are representative of three independent
experiments. Abbreviations are: N, normoxia; H, hypoxia. Equivalent
intensity of actin protected species in all lanes indicates that sample
processing and gel loading was comparable for all specimens.
shown). Incubation with BQ-123 did not inhibit basal DNA
synthesis (Fig. 7B). These results suggest that the ETB receptor
selectively mediates the mitogenic effect of endogenous or exog-
enous ET-1 in human tubular cells.
Fig. 1. Immunoreactive endothelin in nonnal human kidney. (A) Renal cortex (X100) — proximal and distal cortical tubules (dct) stained positively for ET-1;
(B) renal cortex 1)< 100) — control section with no primary antibody; similar results were seen with equivalent concentrations of normal mouse ascites or when
the primaiy antibody was preincubated with 5 sM E1'-l; (C) renal cortex (X 1000) — weak staining in glomerular parietal epithelium (par), glomerular visceral
epithelium (vis) and mesangial cells (m) in addition to distal (dct) and proximal (pt) tubules; (D) renal medulla (X200) — positive staining of inner medullaiy
collecting ducts; (F) renal medulla (X400) — positive staining of inner meduliary collecting ducts (imcd) and thin limbs of ascending loops of Henle (talh);(F) renal medulla (><200) — control section stained with primaly antibody preincubated with 5 M ET-1; similar results were seen when equivalent
concentrations of mouse ascites were used or when the primary antibody was omitted; (G) renal pelvis (X400) — positive staining overlying the multilayered
pelvic epithelium (pci); (H) renal arteiy (x400) — positive staining in endothelium (end). The primary antibody used was a monoclonal antibody to human
ET-1 with equal cross reactivity to Big ET-1 but less than 10% cross reactivity to human ET-2 and ET-3.
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Fig. 4. Effect of hypoxia on ET-1 gene expression in human PTC is not reproduced by cobalt chloride (Co), Hypoxia (1% 02) increased ET-1 mRNA by2.6 0.1-fold after 16 to 24 hours (N = 7). In the latter three experiments, cobaltous chloride (50 M) had no significant effect on ET-1 gene expression:
1.2 0.1 of control (N = 3). Values quoted are means SEM. Details as for Figure 3.
Unexpectedly, incubation with PD-145065 (10 M) was associ-
ated with suppression of endogenous ET-1 synthesis to less than
10% of control values (Fig. 8A). In combination, both agents
resulted in almost complete suppression (3% control) of endog-
enous ET-1 production (Fig. 8A). No difference in cell counts or
cell protein between wells was found to account for these differ-
ences in ET-1 synthesis (data not shown). Also, no significant
difference was observed in ET-1 synthesis between controls and
cells incubated with BQ-123 (10—6 M).
Incubation with the ETB selective agonist, BQ-3020 (10w M)
[40] stimulated tubular ET-1 synthesis by 43 4% (N =10 to 11)
of control cells (Fig. 8B). These results suggest that ET-1 stimu-
lates its own synthesis in human tubular cells by a positive
feedback loop mediated by the ETB receptor.
Discussion
Fig. 5. Aga rose gel showing products of PCR amplification of ETA (299 bp)
and ETB (428 bp) cDNA from six separate cultures of human PTC (lanes 2
to 7). Lane 1 is a negative control (no template) and Lane 8 is a 100 bp
DNA ladder.
ET-1 stimulates its own synthesis via the ETB receptor
Incubation with phosphoramidon (10 M) alone suppressed
ET-1 release to 25% of control values over 24 hours (Fig. 8A).
The mechanisms underlying repair and regeneration of renal
tubular cells after ischemic acute renal failure remain poorly
defined [1]. Clearly, where there is extensive tubular cell death,
tubular regeneration from surviving cells must increase in parallel
to maintain nephron integrity. How this complex process is
initiated is not known, but surviving cells appear to express
markers normally associated with dedifferentiation (vimentin ex-
pression) and mitogenesis (proliferating nuclear cell antigen, c-fos
expression) after an ischemic insult [2]. We hypothesized that a
major part of this regenerative process could involve hypoxic
induction or up-regulation of an autocrine growth factor in
surviving cells, leading to appropriate 'autoregeneration' and thus
reconstitution of the injured renal tubule.
Because the renal microcirculation is particularly sensitive to
the vasoconstrictor action of ET-1 [41], much work has focused on
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Fig. 6. Binding characteristics of '251-ET-1 at 37°C by human PTC assessed
by (A) saturation binding with increasing concentrations (1 to 1000 pM) of
1251ET-1. The figure shows a representative experiment of three per-
formed in duplicate: total binding (0), specific binding (0) and non-
specific binding (). Inset. Scatchard plot of the same experiment. (B)
Competition binding of 1251-ET-1 (100 pM) in the presence of increasing
concentrations of unlabeled ET-1 (LI) or ET-3 (A). Specific binding is
expressed as a percentage of total binding (100%) in the absence of
competing lignd. Non-specific binding was assessed as the binding of
1251-ET-1 in the presence of a thousand-fold excess of cold ET-1. Data
shown are means of duplicate determinations and are representative
experiments of five performed.
the pathophysiological role of ET-1 in ischemic acute renal
failure. The most convincing evidence of such a role comes from
studies in rodents where administration of an anti-endothelin
antibody, either before [42] or after [43] the onset of renal
ischemia, appeared to ameliorate the typical vasoconstriction and
histological changes of the post-ischemic kidney. Most attention
has thus been directed towards the effects that ET-1 might have
on vascular tone or glomerular function. However, several obser-
vations suggest that the pathophysiological involvement of ET-1
in these models may not be solely related to vascular or glomer-
ular events. First, no differences in either number or affinity of
glomerular endothelin receptors between ischemic and control
kidneys were found after a 60-minute ischemic period at a time
when glomerular filtration rate (GFR) and glomerular plasma
flow (QA) were less than 5% of control values [44]. Second, in a
model of severe acute renal failure, the ETA receptor antagonist
BQ-123, administered 24 hours after renal ischemia, initiated
recovery of tUbular function while glomerular filtration remained
markedly depressed [45].
Since most of our knowledge of the localization of endothelin
A
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Fig. 7. Effect of exogenous and endogenous endothelins on DNA synthesis,
as assessed by [3H]-thymidine incolporation, in quiescent human FTC. (A)
Effect of increasing concentrations (10 to i0 M) of exogenous ET-1
(D), ET-2 (O) and ET-3 (0); the Figure shows mean increases in
thymidine incorporation above control of triplicate wells taken from a
representative experiment (N = 2); error bars have been omitted for the
sake of clarity but did not exceed 10% of the mean for each point. Each
point was significantly different from controls, but there was no significant
difference between ET-1, ET-2 and ET-3 at each concentration tested. (B)
Effect of phosphoramidon (Phos, iO M), BQ-123 (10 M) and PD-
145065 (PD, iO M) on basal DNA synthesis; N = 16 from four
experiments. Results are expressed as a percentage of control (100%) to
enable comparison between different experiments; each bar represents
mean SEM. Exogenous ET-1 (10- M) elicited no significant increase in
[3H-thymidine incorporation: 101.2 3.3%. * P < 0.05 vs. control.
synthesis and its potential functions in the kidney comes from
—
animal studies, in particular from the rat, it should be noted that
important species differences between rat, dog and humans have
been found. These include the anatomical localization of endo-
thelin receptors [46—48], the isoforms of endothelin found [21]
and the endothelin receptor subtype mediating renal vascular
responses or tubular sodium excretion [481. For these reasons,
animal models are less than ideal for studying relevant fUnctions
of endothelins in the healthy and diseased human kidney. Since
the pathophysiology of renal ischemia is complex [49] and multi-
ple renal cells synthesize endothelins [50], we chose an in vitro
model of human renal proximal tubular cells to investigate the
possibility that tubular-derived endothelins might function as
autoregenerative factors in human renal proximal tubules follow-
ing ischemia.
Using immunohistochemical techniques, we were able to local-
ize ET-1 peptide in different segments of the human nephron,
including the proximal tubule. Nevertheless, the presence of
immunoreactive peptide does not prove de novo synthesis. In the
absence of in situ hybridization studies demonstrating tubular
— localization of ET-1 mRNA, it is possible that immunoreactive
—6 tubular ET-1 staining, especially in the proximal tubule, could
represent uptake of filtered ET-1 peptide.
Unlike others [51, 52], we did not find strong staining of the
vasa recta or glomeruli. These differences may be either species or
technique related. The immunoreactivity of IMCD cells was also
less than expected from animal studies [16, 17] since cells from
this segment seem to produce the highest ET-1 concentrations in
vitro. However, a study of ET-1 synthesis by human IMCD cells
found much lower ET-1 concentrations than those produced by
rat IMCD cells [53]. The significance of papillary staining is
unclear.
The RNAase protection assay and RP-HPLC/radioimmunoas-
say studies showed that cultured human proximal tubular cells
express ET-1 and ET-2 mRNA and synthesize both ET-1 and
ET-2 peptides under basal and stimulated conditions. ET-2 gene
expression has been described in fetal human kidney [54], but this
is the first demonstration of ET-2 gene expression by cells of adult
human kidney.
Not only do cultured human proximal tubular cells synthesize
endothelins, but they also express binding characteristics and
mRNA for both endothelin receptor subtypes, that is, ETA and
ETB. Although their functions have not been defined so far, ETB
receptors are the major receptor subtype expressed in the kidney
[47, 48], mainly by tubular cells [55, 56]. In addition, rat proximal
tubular cells appear to express a subpopulation of ETA receptors
in vitro [37] and in vivo [45], though this has been disputed [55].
Since we found a 6:1 ratio of ETA to ETB receptors, it seems likely
that ET receptors are down-regulated in vitro.
Several lines of evidence suggest that ET-1 acting via ETB
receptors is an autocrine growth factor in human renal proximal
tubular cells. Firstly, phosphoramidon, which reduces basal ET-1
production by inhibiting the ET-1 converting enzyme [57], de-
creased basal DNA synthesis. Secondly, blockade of ETA and ETB
receptors (by PD-145065) reduced basal mitogenesis, but selective
blockade of ETA receptors (by BQ-123) did not. Thirdly, where
seen, the mitogenic response to exogenous endothelins, that is,
ET-1, ET-2 and ET-3 appeared to be roughly equipotent and
could be blocked by PD-145065, indicating that this was mediated
through the non-selective ETB receptor subtype. These results
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small (20 to 40% increase) and comparable to the increase we
noted with BQ-3020 (Fig. 8B). Given the 10-fold decrease seen
with effective ETB receptor blockade (PD-145065), the small
magnitude of both these effects could reflect the already 'near
maximal' stimulation of ET-1 synthesis by endogenous ET-1.
Since proximal tubular ET-1 synthesis in vivo is likely to be low,
this phenomenon suggests a mechanism by which an increase in
proximal tubular ET-1 gene expression (for example, by hypoxic
induction) may contribute significantly towards the previously
unexplained long-lasting induction of ET-1 gene expression in the
post-ischemic kidney [21]. These findings thus point to a novel
function for tubular ETB receptors in mediating both mitogenesis
and autoinduction of ET-1 synthesis, which differs from that of
tubular ETA receptors, which probably mediate sodium handling
[45].
— Recent studies have reported the beneficial effects of the
100 selective ETA receptor blocker, BQ-123 in initiating tubular
regeneration in a rat model of severe acute renal failure, inde-
pendent of its effect on glomerular filtration rate and renal plasma
flow [45, 60]. This was a surprising finding since there has been
some dispute as to whether rat tubular cells express ETA receptors
[37, 55]. Although the role of tubular ETB receptors was not
addressed in these studies, blockade of tubular ETA receptors
could have 'favored' a mitogenic response to tubular-derived ET-1
via tubular ETB receptors. Together with our findings, this would
imply a different pathophysiological role for each receptor sub-
type in ischemia such that potentially different and opposing
effects, that is, 'dysfunction' (via ETA) and 'regeneration' (via
ETB) could result from increased tubular ET-1 synthesis. Indeed,
the severity of the ischemic insult may be the most important
determinant of which effect predominates, since no effect of
BQ-123 has been found in models of acute renal failure of lesser
severity, where early tubular regeneration would be the norm [45].
The effect of hypoxia on tubular ET-1 gene expression was
specffic for this endothelin isoform, since ET-2 gene expression
did not change and ET-3 gene expression was not induced.
Although hypoxic induction of the ET-1 gene has been reported
in endothelial cells [22], the effect of hypoxia on ET-2 and ET-3
gene expression in other cell types has not been previously
described. Moreover, the hypoxic induction of tubular ET-1 gene
expression is particularly significant since, unlike endothelial cells,
we [24] and others [61] have found few agents that consistently
up-regulate tubular ET-1 production. For example, we have
previously found that only phorbol myristate acetate (PMA) and
human high density lipoproteins (HDL) consistently increased
tubular ET-1 mRNA levels and peptide synthesis [24]. Thus it
seems likely that the regulation of the ET-1 gene differs between
tubular epithelial cells and endothelial cells [24, 62, 63].
It has been reported that lesser degrees of hypoxia (10% 02) in
vivo increase ET-1 gene expression in the lung and cardiac atrium
but not kidney [64]. This suggests that the renal threshold for
hypoxic up-regulation of the ET-1 gene might be lower than in the
other two organs. The mechanism by which ET-1 gene expression
is increased by hypoxia in cultured human PTC is not known, but
the fact that cobaltous chloride does not increase ET-1 mRNA
levels suggests that it is different from that which regulates
erythropoietin [33].
In summaly, we have presented evidence that that human renal
proximal tubular cells synthesize ET-1 and ET-2 constitutively
and that ET-1, acting via ETB receptors, is an autocrine growth
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Fig. 8. Tubular ET-1 synthesis (pg/mi) over 24 hours. (A) Effect of phos-
phoramidon (Phos, iO M), BQ-123 (106 M) and PD-145065 (PD, iO
M); N = 9 to 11 from four experiments; (B) the effect of BQ-3020 (10
M); N = 10 to 11 from three experiments. < 0.05 vs. control.
show that, unlike rat mesangial cells [58] and rat vascular smooth
muscle cells [39], ETB receptors mediate the mitogenic response
to endothelins in human tubular cells.
A surprising finding was that antagonism of the ETB receptor
by PD-145065 was associated with marked suppression of endog-
enous ET-1 synthesis. A likely explanation for this finding is that
antagonism of the ETB receptor interrupts a positive feedback
loop by which endogenous ET-1 induces its own synthesis. Auto-
induction of ET-1 synthesis via the ETB receptor has been
described in human endothelial cells [59]: the effect seen was
400 Ong et al: ET-1 mediated tubular regeneration
factor for these cells. In conjunction with the demonstration that
the endothelins are mitogenic, the specific up-regulation of ET-1
gene expression by hypoxia, and the possibility that ET-1 can
induce its own synthesis in these cells, provides a plausible
mechanism whereby tubular ET-1, acting via ETB receptors, may
be involved in the regenerative response of surviving tubular cells
to ischemic injury. Preliminary observations have also shown that
hypoxia itself stimulates DNA synthesis in quiescent human
tubular cells [65], and that this response is associated with specific
down-regulation of ETB receptor number (unpublished data).
Further studies are being conducted as to the precise contribution
of the ET-1/ETB growth loop in this response, as well as the
importance of this autoregenerative system in vivo.
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